Compare RKDA & AEMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RKDA | AEMD |
|---|---|---|
| Founded | 2002 | 1984 |
| Country | United States | United States |
| Employees | N/A | 9 |
| Industry | Agricultural Chemicals | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9M | 2.1M |
| IPO Year | 2015 | 2008 |
| Metric | RKDA | AEMD |
|---|---|---|
| Price | $0.67 | $0.89 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 4.9M | 316.9K |
| Earning Date | 05-07-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 66.92 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,858,000.00 | N/A |
| Revenue This Year | $61.67 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.65 | $0.51 |
| 52 Week High | $6.71 | $5.89 |
| Indicator | RKDA | AEMD |
|---|---|---|
| Relative Strength Index (RSI) | 29.97 | 24.61 |
| Support Level | N/A | $0.51 |
| Resistance Level | $1.51 | $2.47 |
| Average True Range (ATR) | 0.16 | 0.19 |
| MACD | -0.02 | -0.12 |
| Stochastic Oscillator | 1.60 | 5.29 |
Arcadia Biosciences Inc is a company with science-based approaches to develop high value products and drive innovation in the consumer goods industry. The company has one operating and reportable segment, which derives revenue from the sale of Zola coconut water. The company's consumer brands in the food, beverage, and body care categories, and others. Its products include: Zola Coconut Water, and Agronomic Wheat Traits. Geographically, the company operates in United States, Argentina, India, and Canada. It derives maximum revenue from United States.
Aethlon Medical Inc is a medical therapeutic company focused on developing the Hemopurifier (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression. The Hemopurifier utilizes a proprietary lectin-based technology to bind and remove enveloped viruses and EVs from biological fluids. EVs have been associated with immune suppression, metastasis, and resistance to therapy in cancer, as well as progression of severe infectious diseases. The Company operates as a single reportable segment.